Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, 310014, PR China; Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, 310014, PR China.
Department of General Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, 310014, PR China.
Cancer Lett. 2019 Mar 31;445:57-64. doi: 10.1016/j.canlet.2018.10.045. Epub 2019 Jan 11.
Pancreatic cancer (PC), one of the most lethal diseases, remains a challenging problem. Novel cancer therapy targeting the immune system has been explored. Although immunotherapy has yielded a favorable response in pre-clinical models, no significant improvement has been confirmed in clinical trials for PC. This may be partly attributable to the unique immunosuppressive tumor microenvironment of PC. Studies focusing on combination therapy showed the ability to break the immunosuppressive tumor microenvironment and enhance the immune response, which can translate to clinical benefits. Moreover, the application of sequencing techniques and neo-antigen vaccines has achieved promising results in clinical trials, which promote the development of personalized immunotherapy. However, lack of effective biomarkers is another challenge for the realization of personalized immune medicine. Biomarkers are urgently needed to identify subgroup of patients who would benefit from immunotherapy. In this review, we discuss advances in immunotherapy for pancreatic cancer, as well as the challenges and prospects for personalized immune medicine.
胰腺癌（PC）是最致命的疾病之一，仍然是一个具有挑战性的问题。目前正在探索针对免疫系统的新型癌症疗法。尽管免疫疗法在临床前模型中产生了有利的反应，但在 PC 的临床试验中并未得到证实有显著改善。这可能部分归因于 PC 独特的免疫抑制性肿瘤微环境。专注于联合治疗的研究表明，其具有打破免疫抑制性肿瘤微环境和增强免疫反应的能力，从而转化为临床获益。此外，测序技术和新抗原疫苗的应用在临床试验中取得了可喜的结果，促进了个性化免疫治疗的发展。然而，缺乏有效的生物标志物是实现个性化免疫医学的另一个挑战。迫切需要生物标志物来识别将从免疫治疗中受益的亚组患者。在这篇综述中，我们讨论了胰腺癌免疫治疗的进展，以及个性化免疫医学的挑战和前景。
